GM Advisory Group’s Vanda Pharmaceuticals VNDA Stock Holding History

GM Advisory Group’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-15,000	Closed	-$239K	–	123
2016 Q4	$239K	Buy	+15,000	New	+$241K	0.08%	94

Other funds holding VNDA

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GM Advisory Group's VNDA Position: Q1 2017 in Review

GM Advisory Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2017, closing a stake of 15,000 shares — an estimated $239K sold.

GM Advisory Group first reported a position in VNDA in Q4 2016 and held it in 1 quarter. The position peaked at $239K in Q4 2016. 136 funds tracked by Wall St. Rank hold VNDA as of Q1 2017.

GM Advisory Group reported no remaining Vanda Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
GM Advisory Group sold 15,000 Vanda Pharmaceuticals shares in Q1 2017, an estimated $239K.
GM Advisory Group first reported a position in Vanda Pharmaceuticals in Q4 2016 and held it in 1 quarter.
GM Advisory Group's Vanda Pharmaceuticals position peaked at $239K in Q4 2016.
136 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2017.

Based on GM Advisory Group's 13F filing for Q1 2017, filed 12 May 2017.